A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC)-MedSci.cn

A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC)

Wang, WH; Li, JC; Li, T; Zhao, KL; Yu, R; Wang, WQ; Chen, MQ; Liang, L; Zou, JY; Wang, YD; Shen, W; Wu, Z; Xiao, ZF